MedTrace Logo

Safety and Efficacy of MEM 1003 Versus Placebo for the Treatment of Patients With Bipolar I Disorder

NCT00374920 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2008-05-06

No results posted yet for this study

Summary

The purpose of this study is to establish the potential of MEM 1003 as a safe and effective treatment for patients with an acute manic or mixed episode of bipolar disorder.

Conditions

  • Bipolar Disorder With Manic or Mixed Episodes

Interventions

DRUG

MEM 1003

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Memory Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Stephen R Murray, MD, PhD · Memory Pharmaceuticals Corp

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2006-12-31
Completion
2007-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00374920 on ClinicalTrials.gov